Tower Research Capital LLC (Trc) Aridis Pharmaceuticals, Inc. Call Options Transaction History

Tower Research Capital LLC (Trc)

  • $3.68 Billion
  • Q3 2024

Call Options

0 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
No transaction found.

Others Institutions Holding ARDS

# of Institutions
2
Shares Held
50.2K
Call Options Held
0
Put Options Held
0
View Full List

About Aridis Pharmaceuticals, Inc.

ARDS Quotes by TradingView
  • Ticker ARDS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 17,701,600
  • Description
  • Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the...
More about ARDS
Track This Portfolio

Track Tower Research Capital LLC (Trc) Portfolio

Follow Tower Research Capital LLC (Trc) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email